Home › Cases › Hypercalcaemia — Malignancy
Hypercalcaemia
Hypercalcaemia — Malignancy
6 questions
Question 1 · Mechanisms
Correct answer: Humoral hypercalcaemia of malignancy (PTHrP) OR osteolytic bone metastases. Breast cancer: usually osteolytic metastases releasing local cytokines + systemic PTHrP
Why
Malignancy hypercalcaemia mechanisms:
- PTHrP (parathyroid hormone-related protein) — secreted by tumour, most common (80%). Lung SCC, breast, renal, bladder. PTH LOW
- Osteolytic metastases — local osteoclast activation. Breast, myeloma
- 1,25-OH vitamin D production: lymphomas (macrophages)
- Ectopic PTH: very rare
Key point
Malignancy: PTHrP (80%, low PTH), osteolytic mets (breast/myeloma), lymphoma (1,25-OHD). PTH low distinguishes from hyperparathyroidism.
Question 2 · Differentiating primary vs malignancy
Correct answer: Primary hyperparathyroidism — elevated PTH with hypercalcaemia and hypophosphataemia; normal ALP does not exclude bone metastases
Why
High Ca2+ with raised/inappropriately normal PTH indicates PTH-dependent hypercalcaemia; PHPT is most likely among these options. PTH increases renal phosphate excretion, causing low phosphate. Consider FHH/tertiary disease in the appropriate context. ALP may be normal or raised; it can reflect bone or liver disease, and a normal value does not exclude bone metastases. Malignancy-related hypercalcaemia usually suppresses PTH; low PTH prompts investigation of malignancy and other PTH-independent causes.
Key point
High Ca2+ + high/inappropriately normal PTH + low PO4 = PTH-driven (usually PHPT; consider FHH). Low PTH: think malignancy, sarcoid or vitamin D. Normal ALP doesn't exclude bone metastases.
Question 3 · Bisphosphonates
Correct answer: IV bisphosphonate: zoledronate 4mg IV over 15 minutes OR pamidronate 60-90mg IV over 2-4 hours. Inhibits osteoclast activity, maximal effect at 72-96h
Why
IV bisphosphonates: zoledronate (first-line — faster, single dose 4mg, effect at 72h, duration 4-6 weeks) or pamidronate (60-90mg, slower). Mechanism: osteoclast inhibition → reduces bone resorption. Renal monitoring required (nephrotoxic — check creatinine pre-infusion). Furosemide: no longer recommended routinely (can worsen dehydration).
Key point
Malignancy hyperCa: IV zoledronate 4mg (first-line, rapid, 4-6 week effect) after adequate hydration. Furosemide no longer recommended.
Question 4 · Denosumab
Correct answer: Denosumab 120mg SC with specialist oversight — not renally cleared, but severe renal impairment increases hypocalcaemia risk
Why
Denosumab binds RANKL (receptor activator of NF-κB ligand), inhibiting osteoclast formation and activation. It is not renally cleared, but CrCl <30 markedly increases hypocalcaemia risk: monitor calcium closely. Use for hypercalcaemia of malignancy is off label in the UK, including bisphosphonate-refractory disease. Rebound hypercalcaemia can occur after stopping.
Key point
Denosumab (anti-RANKL) can treat malignant hypercalcaemia when bisphosphonates are unsuitable. Not renally cleared ≠ no risk: monitor for hypocalcaemia.
Question 5 · Hypercalcaemic crisis
Correct answer: IV 0.9% saline 200–500 mL/h initially, with frequent reassessment; IV bisphosphonate once rehydration established, calcitonin bridge and urgent ICU monitoring
Why
Ca2+ >3.5 with reduced GCS: life-threatening. 0.9% saline 200–500 mL/h, reassessing fluid balance often; restores volume and increases renal calcium excretion. Calcitonin 4 IU/kg SC/IM works in 4–6 h (max 48–72 h). IV bisphosphonate once rehydrated: works in 2–4 days, sustained effect. Steroids for calcitriol-driven sarcoid/lymphoma; dialysis if severe renal failure.
Key point
Crisis: saline, calcitonin bridge, IV bisphosphonate. If bisphosphonate unsuitable: specialist denosumab (UK off-label; watch hypocalcaemia in CKD).
Question 6 · Myeloma hypercalcaemia
Correct answer: Predominantly osteolytic disease: DKK1 inhibits osteoblasts and RANKL activates osteoclasts. Isotope bone scans may miss lesions; treat myeloma plus antiresorptive therapy
Why
Myeloma bone disease: DKK1 (Dickkopf-1) inhibits osteoblast differentiation; RANKL activates osteoclasts → predominantly lytic lesions with impaired bone formation. Isotope bone scans may miss disease; do not use them to identify myeloma bone disease.
- Suspected myeloma: consider whole-body MRI first; low-dose CT if MRI unsuitable/declined
- Zoledronate reduces skeletal events; haematology leads myeloma treatment (e.g. VTd: bortezomib, thalidomide, dexamethasone, if previously untreated and transplant-eligible)
Key point
Myeloma: lytic disease via DKK1/RANKL. Avoid isotope bone scans; whole-body MRI, or low-dose CT if unsuitable. Treat myeloma plus zoledronate when appropriate.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.